Incyte Faces Growth Challenges: Will Opzelura Close the $2.4 Billion Jakafi Shortfall?

Opzelura: Promising Beginnings, Challenging Growth

Opzelura entered the market with impressive momentum, quickly surpassing initial company forecasts. In its fourth full year, the drug achieved 33% annual growth, reaching $678 million in 2025. The strong performance continued into the fourth quarter, with sales rising 28% to $207.3 million and exceeding expectations. This growth was further supported by the expansion into pediatric atopic dermatitis, targeting children aged 2 to 11, which is now generating $30 million annually.

However, the outlook for 2026 reveals a slowdown. Incyte projects Opzelura sales between $750 million and $790 million, representing only a 15% increase from 2025—a notable drop from the previous year’s 33% growth. This projection also falls short of analysts’ expectations of $801.5 million. The data suggests that the initial boost from new indications and market expansion may be tapering off, and achieving further scale will be more challenging than previously thought.

Company leadership has acknowledged these hurdles. CEO Bill Meury pointed to "price actions to expand formulary coverage" as a factor limiting volume growth, indicating that broader market access may come at the expense of pricing strength. While management remains optimistic about Opzelura’s potential—especially as the non-steroidal market segment grows—the 2026 forecast suggests that significant expansion is still some years away. The company’s growth engine is active, but not yet at the pace needed to close the valuation gap as Jakafi’s patent expiration approaches.

The Impending Challenge: Jakafi’s Patent Expiration and the Role of the Pipeline

Jakafi’s looming patent expiration is a pivotal issue for Incyte’s future. The drug accounted for 60% of Incyte’s revenue last year and is expected to bring in $3.22 to $3.27 billion in 2026. With patent protection ending in late 2028, Incyte faces a significant revenue drop. To put this in perspective, Jakafi’s 2026 sales are over four times greater than the rest of the company’s portfolio combined.

To counteract this, Incyte is focusing on expanding its newer products and pipeline. For 2026, the company anticipates that its hematology and oncology products, excluding Jakafi, will generate $800 million to $880 million—a substantial increase from $583 million in 2025, reflecting over 37% growth. Despite this progress, the gap remains wide: even with strong growth, there will still be a shortfall of approximately $2.4 billion in annual sales by 2029 that must be addressed.

The company’s pipeline is central to bridging this divide. Incyte plans to have fourteen pivotal clinical trials underway by the end of the year, including a CDK2 inhibitor for solid tumors—a promising area. This ambitious late-stage pipeline is a bet on the company’s ability to consistently introduce new, scalable revenue streams. However, the journey from clinical trials to commercial success is lengthy and uncertain, and the pipeline’s true value will depend on its ability to deliver multiple successful products in a short period.

Ultimately, Incyte is racing to grow its non-Jakafi business to a substantial share of current Jakafi revenues before the patent expires. While 2026 guidance shows progress, the leap from $583 million to several billion dollars is steep. The company’s ability to scale hinges on the successful execution of its pipeline strategy, making the next few years a crucial test of its growth capabilities.

Investor Outlook: Valuation and Growth Considerations

From a growth investor’s perspective, Incyte is at a crossroads. The company posted strong results in 2025, with total revenue rising 21% year-over-year to $5.14 billion. However, the market’s reaction was muted—shares fell about 5% after the February 10 earnings release and have since hovered around $102. This response reflects investor concerns about the company’s ability to replace Jakafi’s revenue as the patent cliff approaches.

The main issue is whether the current share price accurately reflects the risks involved in this transition. Incyte’s 2026 guidance for total net product revenue of $4.77 to $4.94 billion is well below Wall Street’s consensus of $5.52 billion. This gap is largely due to slower-than-expected growth for Opzelura and the daunting task of scaling the pipeline to offset Jakafi’s decline. For growth-focused investors, the concern is not just about missing short-term targets, but about whether the company can build a sustainable, scalable business model for the future. The recent 30-day return of -10.56% underscores the market’s cautious stance as investors reassess the likelihood of achieving a $3 to $4 billion ex-Jakafi business by 2030.

Looking ahead, the company’s valuation will depend on its ability to deliver on its pipeline promises and achieve market leadership before Jakafi’s exclusivity ends. While some analysts still see value in the stock, its proximity to 52-week highs and ongoing guidance shortfalls keep attention focused on the challenges ahead. The growth narrative remains, but the timeline is now under greater scrutiny.

Key Catalysts and Risks for 2026

The coming year will be pivotal for Incyte and its investors. The company’s ability to scale its pipeline and convert potential into real market share will be closely watched. Several critical factors and events will shape the story in 2026:

• Opzelura Sales Performance: Incyte’s 2026 forecast of $750 million to $790 million for Opzelura implies a 15% growth rate, a slowdown from 2025’s 33%. Investors will be watching to see if the company can meet or exceed this target, especially as the pediatric segment grows and pricing strategies evolve. Any significant miss could signal deeper issues with scaling the core business.
• Pipeline Milestones: Progress in the company’s fourteen pivotal clinical trials will be a major catalyst. Updates on the CDK2 inhibitor for solid tumors are particularly anticipated. Positive trial results could validate Incyte’s innovation strategy, while setbacks would increase pressure on existing products to deliver growth.
• Execution Risk: The biggest challenge remains whether Opzelura and the pipeline can scale quickly enough to offset Jakafi’s decline. With Jakafi expected to generate over $3.22 billion in 2026 and the rest of the business targeting $800 million to $880 million, a $2.4 billion gap must be closed by 2029. If the pipeline’s development lags, Incyte may be forced to rely too heavily on Opzelura, making it difficult to achieve the growth rates needed to support its valuation.

In summary, Incyte’s future will be defined by its ability to execute on its ambitious pipeline and scale new products before Jakafi’s patent expires. The next several quarters will reveal whether the company is making meaningful progress or simply managing through a period of transition.